RecruitingNot ApplicableNCT06877169

Staged Kidney Transplantation During Combined Heart/Kidney Transplantation


Sponsor

Cedars-Sinai Medical Center

Enrollment

20 participants

Start Date

Apr 7, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The primary purpose of this study is to evaluate the safety and efficacy of ex vivo machine perfusion with staged implantation of kidney allografts during combined heart/kidney transplantation.


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • Adult patients (18 years or older) undergoing combined heart and kidney transplantation at Cedars-Sinai Medical Center.

Exclusion Criteria2

  • Patients who undergo simultaneous heart/kidney transplantation in a single operative event due to medical necessity will be excluded.
  • Patients with medical records flagged as "break-the-glass" or "research opt-out" within the center's electronic health record.

Interventions

OTHERPlanned delayed implantation of kidney allograft with ex vivo machine perfusion kidney preservation.

During combined heart and kidney transplantation, heart and kidney allografts may be implanted during a single operative event, or with delayed kidney implantation in a second operative event. Timing of the delay is often determined by recipient stability and kidney availability; however, clinicians must balance recipient factors with accumulating cold ischemic time of the kidney allograft. This study uses hypothermic oxygenated machine perfusion to reduce ischemic injury to the kidney allograft and allow for improved recipient stability with planned delayed implantation of the kidney graft. Delays will allow for at least 6 hours of hypothermic oxygenated machine perfusion prior to implantation.


Locations(1)

Cedars-Sinai Medical Center

Los Angeles, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06877169


Related Trials